first

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…

4 days ago

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…

5 days ago

Bavarian Nordic Announces Interim Results for the First Nine Months of 2024

COPENHAGEN, Denmark, November 15, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first…

6 days ago

Sweden becomes first country in the world to apply for Trademark

The application comes as Visit Sweden looks to Prevent Travel Mix-Ups Among Tourists STOCKHOLM, Nov. 12, 2024 /PRNewswire/ -- Sweden…

1 week ago

Silverfort Acquires Rezonate, Expanding its Cloud Identity Security Offering to Deliver the First Complete Identity Security Platform

With Rezonate's acquisition, Silverfort continues to break down identity security silos across all enterprise environments, on-prem and in the cloud,…

1 week ago

Sweden becomes first country in the world to apply for Trademark

The application comes as Visit Sweden looks to Prevent Travel Mix-Ups Among Tourists STOCKHOLM, Nov. 12, 2024 /PRNewswire/ -- Sweden…

1 week ago

Alliance University Awarded A+ Accreditation by NAAC in First Assessment Cycle

This A+ accreditation achievement is reflected in the varsity's cumulative CGPA of 3.26. BANGALORE, India, Nov. 12, 2024 /PRNewswire/ -- Alliance…

1 week ago

India IVF, one of India’s First Tech-Enabled Fertility Platform, Secures $1.25 Million Investment from Tomorrow Capital

GURGAON, India, Nov. 11, 2024 /PRNewswire/ -- India IVF, a pioneering fertility provider founded by Dr. Richika Sahay and Dr. Somendra…

1 week ago

ALK licenses rights to neffy, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS…

1 week ago

Approx. USD 4.0 M Invested in Product Development for NTDs – GHIT’s First Investment in the Development of Diagnostics for Trachoma

TOKYO, Nov. 7, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY…

2 weeks ago